Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP)

15.80
Delayed Data
As of 3:59pm ET
 +0.05 / +0.32%
Today’s Change
9.59
Today|||52-Week Range
18.75
-8.62%
Year-to-Date
5 Best Small-Cap Stocks for 2017
11:06am / Zacks.com - Paid Partner Content
This Value Screen Is Our Top Performer This Year
Nov 29 / Zacks.com - Paid Partner Content
Bristol-Myers Reports Data from Opdivo Combination Studies
10:07am / Zacks.com - Paid Partner Content
The Pockets of Speculative Action Have Dried Up
Nov 29 / TheStreet.com - Paid Partner Content
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
9:03am / Zacks.com - Paid Partner Content
Nivalis (NVLS) Cystic Fibrosis Study Misses Primary Endpoint
Nov 29 / Zacks.com - Paid Partner Content
Acceleron, Celgene Present Myelodysplastic Syndromes Data
Dec 05 / Zacks.com - Paid Partner Content
Recro Pharma (REPH) in Focus: Stock Moves 19.8% Higher
Nov 29 / Zacks.com - Paid Partner Content
Alexion Presents Data from Ultra-Rare Blood Disorder Study
Dec 05 / Zacks.com - Paid Partner Content
Heat Biologics (HTBX) in Focus: Stock Moves 30.4% Higher
Nov 28 / Zacks.com - Paid Partner Content
What Makes Concordia International (CXRX) a Strong Sell?
Dec 05 / Zacks.com - Paid Partner Content
Looking for a Growth Stock? Why it is Time to Focus on Sucampo Pharmaceuticals (SCMP)...
Nov 25 / Zacks.com - Paid Partner Content
Heat Biologics Stock Falls on Negative Bladder Cancer Data
Dec 01 / Zacks.com - Paid Partner Content
Glaxo Nucala Favorable in Rare Vasculitis Disease Study
Nov 24 / Zacks.com - Paid Partner Content
Achaogen (AKAO) Catches Eye: Stock Adds 6.5% in Session
Dec 01 / Zacks.com - Paid Partner Content
Why Sucampo Pharmaceuticals (SCMP) Could Be Positioned for a Surge
Nov 23 / Zacks.com - Paid Partner Content
Cytori Scleroderma Study Two-Year Follow-Up Data Published
Nov 30 / Zacks.com - Paid Partner Content
Oragenics Jumps on Fast Track Status for Oral Mucositis Drug
Nov 23 / Zacks.com - Paid Partner Content
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
Nov 30 / Zacks.com - Paid Partner Content
Bristol-Myers' Opdivo Gets EU Approval for Label Expansion
Nov 23 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Su...
Nov 30 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and...
Nov 22 / Zacks.com - Paid Partner Content
Sucampo (SCMP) Worth a Look: Stock Jumps 6.2% in Session
Nov 30 / Zacks.com - Paid Partner Content